CRISPR Activation (CRISPRa) Library

Gain-of-Function Screening — A New Era of Gene Activation

Gene function research needs not only "knockout" but also "activation" to explore overexpression effects. Traditional overexpression requires vector construction — slow and unsuited for high-throughput screens. Moreover, exogenous overexpression cannot recapitulate endogenous regulation.

GeneRulor CRISPRa Library Service directly activates endogenous genes while preserving regulatory elements and splicing patterns for physiological studies.

Figure 1 CRISPRa Library Mechanism Diagram

1. What is a CRISPRa Library?

A CRISPRa library is built on dCas9 fused to transcriptional activation domains (VP64, VPR, or SAM). Guided by sgRNAs to promoter/enhancer regions, it potently activates endogenous gene expression.

2. Core Technical Principles

2.1 Transcriptional Activation Complex Recruitment

The dCas9-activation fusion binds -400bp to TSS to recruit transcriptional activators and enhance RNA Pol II.

2.2 Multiple Activation Systems

• VP64 system: 4 tandem VP16 domains for moderate activation (5-10x)

• VPR system: VP64-p65-Rta triple activation domain, 10-100x activation

• SAM system: dCas9-VP64 plus modified sgRNA for ultra-strong activation (up to 1000x+)

2.3 Advantages of Endogenous Activation

Unlike exogenous overexpression, CRISPRa preserves:

• Complete 5' and 3' UTRs for mRNA stability and translational regulation

• Natural splicing patterns and isoform ratios for physiological relevance

• Chromatin context and epigenetic regulation — no position effects

• Physiological gene dosage, avoiding artefacts of excessive overexpression

Figure 2 CRISPRa Core Principles and Activation Systems

3. GeneRulor One-Stop Service Advantages — Your Research Accelerator

Traditional CRISPR screens require multi-vendor coordination — adding cost, delays, and quality risks.

Choose GeneRulor — one decision covers it all. Backed by a postdoctoral R&D team, integrating five departments: Molecular Biology, Cell Biology, Viral Packaging, Bioinformatics, and NGS, we deliver seven end-to-end workflow steps：

4. Five Core Competencies

• Postdoctoral Station, Elite Team: Expert postdoctoral team for library design and data analysis

• Multi-Department Collaboration, Full-Process QC: Integrating Molecular Biology, Cell Biology, Viral Packaging, Bioinformatics, and NGS Sequencing forming a seamless service chain

• Proprietary Design Algorithms, Superior Knockout Efficiency: Proprietary gRNA algorithms achieve 60-90% knockout efficiency

• Professional Viral Packaging Platform for Hard-to-Transfect Cells: High-titer lentivirus for primary cells, neurons, immune cells, and other hard-to-transfect types

• One-Stop Service — Save Time, Effort, and Hassle: Full-cycle service from design to data; no multi-vendor coordination; 30-50% shorter timelines

5. Applications — Gene Activation Opens a New Era of Gain-of-Function Research

5.1 Drug Resistance Mechanism Studies

Systematically activate genes to identify which upregulation confers drug resistance — applied to venetoclax, immune checkpoint inhibitors, and more.

5.2 Cell Reprogramming and Transdifferentiation

Activate key transcription factors to drive cell fate conversion. Endogenous activation retains fuller regulatory networks, achieving higher efficiency and more stable cell states than exogenous overexpression.

5.3 Disease Gene Functional Validation

Activate GWAS-identified candidate genes to validate their causal roles and pathogenic mechanisms.

5.4 Metabolic Pathway Optimization

Activate rate-limiting enzymes or regulatory factors to optimize metabolic flux — for industrial strain engineering and biosynthesis.

5.5 Enhancer Function Analysis

Target candidate enhancer regions to identify functional enhancers and their target genes, mapping regulatory networks.

5.6 Tumor Immunotherapy Optimization

Activate tumor antigens or immune-stimulatory genes to enhance tumor immunogenicity — successfully applied to develop novel cancer vaccine strategies.

6. High-Impact Publication Case Studies

6.1 Case 1: Nature Immunology 2019 — CRISPRa Empowers Tumor Immunotherapy

Reference:

Chow et al. (2019). Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 20, 1494-1505.

Figure 3 CRISPRa Tumor Immunotherapy Workflow

Background: Immunotherapy has transformed cancer treatment but faces multiple limitations. Researchers asked: could directly activating endogenous antigen genes in tumor cells enhance immunogenicity and trigger powerful anti-tumor immunity?

Approach: The team developed MAEGI (Multiplexed Activation of Endogenous Genes as Immunotherapy), using CRISPRa (SAM) to activate endogenous genes in tumor cells, enhancing antigen presentation and anti-tumor immunity.

Key Findings:

• CRISPRa activation of OVA antigen genes significantly enhanced T cell recognition and killing, even at E:T ratio of 0.5:1

• As a cellular vaccine strategy, CRISPRa-treated tumor cells showed significant efficacy in both prophylactic and therapeutic settings

• Intratumoral AAV delivery of CRISPRa sgRNA libraries triggered potent anti-tumor immunity across breast and colon cancer models

• CRISPRa targeting mutated gene sets eliminated most local and distant tumors — demonstrating an "abscopal effect"

Clinical Significance: This pioneering study demonstrates CRISPRa's enormous immunotherapy potential. MAEGI bypasses key vaccine limitations: no ex vivo loading, no pre-identified antigens, activates multiple antigens to overcome heterogeneity — opening a new direction for next-generation tumor immunotherapy.

6.2 Case 2: Nature Communications 2022 — CRISPRa Identifies Drug Resistance Mechanisms

Reference: Monahan et al. (2022). Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Nature Communications, 13, 4862.

Figure 4 CRISPRa Screen for Venetoclax Resistance Workflow

Background: Venetoclax, a BCL-2 inhibitor, has achieved success in CLL and AML, but acquired resistance is a major challenge. Researchers needed to systematically identify which gene upregulation drives resistance.

Approach: The team created venetoclax-sensitive lymphoma (CRISPRa Bcl-2 in Eμ-Myc) and performed genome-wide resistance screening.

Key Findings:

• Eμ-Myc/CRISPRa/sgBcl-2 mice rapidly developed aggressive lymphomas expressing high BCL-2 and MYC — accurately modeling human double-hit lymphoma (DHL)

• Unlike standard Eμ-Myc lymphomas, BCL-2-high lymphomas were exquisitely venetoclax-sensitive (IC50: 5-10nM)

• Genome-wide CRISPRa screen definitively identified BCL-2 family member A1 (human homolog BFL-1) as the dominant driver of venetoclax resistance

• A1 activation confers resistance and expands BCL-2 inhibitor spectrum — revealing A1 as a new drug target

Clinical Significance: This established an in vivo CRISPRa platform and identified venetoclax resistance mechanisms in a clinically relevant model. A1/BFL-1 provides a clear target to overcome resistance and demonstrates CRISPRa's unique value for prospectively identifying resistance mechanisms.

GeneRulor's one-stop CRISPRa Library Service is designed to help your research reach this level — from cutting-edge library design with multiple activation systems (SAM/VPR) to expert data analysis.

7. Why Choose GeneRulor?

In functional genomics, technology is a tool. The real value is translating techniques into reliable discoveries. Choose GeneRulor for a true research partner:

• Postdoctoral R&D station with deep expertise for your project

• Five integrated departments covering every step

• Every project is unique — personalized design, not one-size-fits-all

• Proven platforms and extensive project experience for complex cell types and demands

• Full-process QC and one-stop service from design to data, no multi-vendor hassle

Partner with us to turn your ideas into high-quality research — from top publications to clinical translation.

References

[1] Chow, R. D., et al. (2019). Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 20, 1494-1505.

[2] Monahan, C. E., et al. (2022). Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Nature Communications, 13, 4862.

[3] Konermann, S., et al. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature, 517, 583-588.

[4] Chavez, A., et al. (2015). Highly efficient Cas9-mediated transcriptional programming. Nature Methods, 12, 326-328.